title: Inhibition of cell motility by troglitazone in human ovarian carcinoma cell line.
abstract: BACKGROUND
  Troglitazone (TGZ) is a potential anticancer agent. Little is known about the effect of this agent on cancer cell migration.
  
  
  METHODS
  Human ovarian carcinoma cell line, ES-2 cells were treated with various concentrations of TGZ. Cell migration was evaluated by wound-healing and Boyden chamber transwell experiments. PPARgamma expression was blocked by PPARgamma small interfering RNA. The effects of TGZ on phosphorylation of FAK, PTEN, Akt were assessed by immunoblotting using phospho-specific antibodies. The cellular distribution of paxillin, vinculin, stress fiber and PTEN was assessed by immunocytochemistry.
  
  
  RESULTS
  TGZ dose- and time-dependently impaired cell migration through a PPARgamma independent manner. TGZ treatment impaired cell spreading, stress fiber formation, tyrosine phosphorylation of focal adhesion kinase (FAK), and focal adhesion assembly in cells grown on fibronectin substratum. TGZ also dose- and time-dependently suppressed FAK autophosphorylation and phosphorylation of the C-terminal of PTEN (a phosphatase). At concentration higher than 10 muM, TGZ caused accumulation of PTEN in plasma membrane, a sign of PTEN activation.
  
  
  CONCLUSIONS
  These results indicate that TGZ can suppress cultured ES-2 cells migration. Our data suggest that the anti-migration potential of TGZ involves in regulations of FAK and PTEN activity.
authors.affiliation: Mackay Medicine, Nursing and Management College, Taipei, Taiwan. eugene@ms2.mmh.org.tw
authors.forename: Yuh-Cheng
authors.initials: YC
authors.lastname: Yang
authors.forename: Tsung-Chuan
authors.initials: TC
authors.lastname: Ho
authors.forename: Show-Li
authors.initials: SL
authors.lastname: Chen
authors.forename: Huei-Yi
authors.initials: HY
authors.lastname: Lai
authors.forename: Ju-Yun
authors.initials: JY
authors.lastname: Wu
authors.forename: Yeou-Ping
authors.initials: YP
authors.lastname: Tsao
mesh_terms: D045744:Cell Line, Tumor; D002465:Cell Movement / Q000187:drug effects* / Q000502:physiology; D002839:Chromans / Q000494:pharmacology* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000473:pathology; D045162:Thiazolidinediones / Q000494:pharmacology* / Q000627:therapeutic use; D000077288:Troglitazone
chemical_list: D002839:Chromans; D045162:Thiazolidinediones; D000077288:Troglitazone